MP0274 / Molecular Partners - LARVOL DELTA

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. (PubMed, JCO Precis Oncol) - No abstract available

Journal • Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors (clinicaltrials.gov) - P1; N=22; Completed; Sponsor: Molecular Partners AG; Active, not recruiting ➔ Completed; N=46 ➔ 22

Clinical • Enrollment change • Trial completion • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors (clinicaltrials.gov) - P1; N=46; Active, not recruiting; Sponsor: Molecular Partners AG; Trial completion date: Sep 2021 ➔ Jan 2022; Trial primary completion date: Jun 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors (clinicaltrials.gov) - P1; N=46; Recruiting; Sponsor: Molecular Partners AG; Trial completion date: Feb 2020 ➔ Sep 2021; Trial primary completion date: Nov 2019 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date